Table 1. Patient characteristics.
| Characteristic | No. of patients (%) | p-value | ||
|---|---|---|---|---|
| TFTD→Rego group | TFTD+Bev→Rego group | Rego→TFTD group | ||
| N = 27 | N = 13 | N = 29 | ||
| Age (years) | 0.314 | |||
| Median (range) | 57 (33–81) | 68 (27–86) | 64 (37–79) | |
| Sex | 0.434 | |||
| Male | 20 (74) | 7 (54) | 20 (69) | |
| Female | 7 (26) | 6 (46) | 9 (31) | |
| ECOG PS | 0.758 | |||
| 0 | 6 (22) | 4 (31) | 6 (21) | |
| 1 | 21 (78) | 9 (69) | 22 (76) | |
| 2 | 0 (0) | 0 (0) | 1 (3) | |
| Primary site | 0.974 | |||
| Right-sideda | 8 (30) | 4 (31) | 8 (28) | |
| Left-sidedb/rectum | 19 (70) | 9 (69) | 21 (72) | |
| Histology | 0.496 | |||
| Adenocarcinoma | ||||
| Well- to moderately differentiated | 25 (93) | 12 (92) | 25 (86) | |
| Poorly differentiated | 1 (4) | 0 (0) | 3 (10) | |
| Mucinous | 0 (0) | 0 (0) | 1 (3) | |
| Unknown differentiation | 1 (4) | 1 (8) | 0 (0) | |
| KRAS status | 0.824 | |||
| Wild-type | 13 (48) | 7 (54) | 14 (48) | |
| Mutant type | 14 (52) | 6 (46) | 14 (48) | |
| Unknown | 0 (0) | 0 (0) | 1 (3) | |
| BRAF status | 0.835 | |||
| Wild-type | 14 (52) | 7 (54) | 14 (48) | |
| Mutant type | 0 (0) | 0 (0) | 1 (3) | |
| Unknown | 13 (48) | 6 (46) | 14 (48) | |
| Disease status | 0.126 | |||
| Advanced | 17 (63) | 11 (85) | 15 (52) | |
| Recurrent | 10 (37) | 2 (15) | 14 (48) | |
| Prior surgery for the primary tumor | 0.427 | |||
| Yes | 21 (78) | 9 (69) | 25 (86) | |
| No | 6 (22) | 4 (31) | 4 (14) | |
| Metastatic site | ||||
| Liver | 18 (67) | 12 (92) | 23 (79) | 0.181 |
| Lung | 18 (67) | 9 (69) | 16 (55) | 0.573 |
| Peritoneum | 5 (19) | 3 (23) | 10 (35) | 0.382 |
| Lymph node | 13 (48) | 3 (23) | 11 (38) | 0.309 |
| No. of metastatic sites | 0.617 | |||
| 1–2 | 19 (70) | 9 (69) | 17 (59) | |
| ≥3 | 8 (30) | 4 (31) | 12 (41) | |
| Prior chemotherapy regimens | 0.863 | |||
| 2 | 14 (52) | 6 (46) | 16 (55) | |
| ≥3 | 13 (48) | 7 (54) | 13 (45) | |
| Prior anti-VEGF antibody therapy | 0.362 | |||
| Yes | 27 (100) | 12 (92) | 27 (93) | |
| No | 0 (0) | 1 (8) | 2 (7) | |
| Prior anti-EGFR antibody therapy | 0.692 | |||
| Yes | 11 (41) | 4 (31) | 13 (45) | |
| No | 16 (59) | 9 (69) | 16 (55) | |
| Time from initiation of first-line chemotherapy | 0.062 | |||
| <18 months | 6 (22) | 9 (69) | 9 (31) | |
| ≥18 months | 20 (74) | 4 (31) | 19 (66) | |
| Unknown | 1 (4) | 0 (0) | 1 (3) | |
Abbreviations: Right-sideda, Cecum, ascending colon, and proximal transverse colon
Left-sidedb, distal transverse colon, descending colon, and sigmoid colon
Rego, regorafenib; TFTD, trifluridine/tipiracil; ECOG PS, Eastern cooperative oncology group Performance status; KRAS, v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog; BRAF, v-raf murine sarcoma viral oncogene homolog B1; VEGF, vascular endothelial growth factor; EGFR, epithelial growth factor receptor.